CD8 + T cell immunodominance in lymphocytic choriomeningitis virus infection is modified in the presence of toll-like receptor agonists

Journal of Virology

Volumn 85, Issue 24, 2011, Pages 13224-13233

  Siddiqui, Sarah ^a   Basta, Sameh ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; LIGAND; LIPOPOLYSACCHARIDE; MYELOID DIFFERENTIATION FACTOR 88; NUCLEOPROTEIN; NUCLEOPROTEIN 396; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PRESENTATION; IMMUNOREGULATION; IN VIVO STUDY; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; VIRUS LOAD;

ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ARENAVIRIDAE INFECTIONS; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; IMMUNOLOGIC FACTORS; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MICE; MICE, INBRED C57BL; TOLL-LIKE RECEPTORS;

LYMPHOCYTIC CHORIOMENINGITIS VIRUS;

EID: 84855848805     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05996-11     Document Type: Article

References (46)

1. Alatery, A., et al. 2010. Cross, but not direct, presentation of cell-associated virus antigens by spleen macrophages is influenced by their differentiation state. Immunol. Cell Biol. 88:3-12.
2. Alatery, A., E. Tarrab, A. Lamarre, and S. Basta. 2010. The outcome of cross-priming during virus infection is not directly linked to the ability of the antigen to be cross-presented. Eur. J. Immunol. 40:2190-2199.
3. Amigorena, S., and A. Savina. 2010. Intracellular mechanisms of antigen cross presentation in dendritic cells. Curr. Opin. Immunol. 22:109-117.
4. Basta, S., and A. Alatery. 2007. The cross-priming pathway: a portrait of an intricate immune system. Scand. J. Immunol. 65:311-319.
5. Basta, S., R. Stoessel, M. Basler, M. van den Broek, and M. Groettrup. 2005. Cross-presentation of the long-lived lymphocytic choriomeningitis virus nucleoprotein does not require neosynthesis and is enhanced via heat shock proteins. J. Immunol. 175:796-805.
6. Brikos, C., and L. A. O'Neill. 2008. Signalling of toll-like receptors. Handb. Exp. Pharmacol. 183:21-50.
7. Cella, M., et al. 1996. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184:747-752.
8. Datta, S. K., and E. Raz. 2005. Induction of antigen cross-presentation by Toll-like receptors. Springer Semin. Immunopathol. 26:247-255.
9. Dunbar, E., A. Alatery, and S. Basta. 2007. Cross-priming of a single viral protein from lymphocytic choriomeningitis virus alters immunodominance hierarchies of CD8+ T cells during subsequent viral infections. Viral Immunol. 20:585-598.
10. Eberl, G., et al. 1996. Immunodominance of cytotoxic T lymphocyte epitopes co-injected in vivo and modulation by interleukin-12. Eur. J. Immunol. 26: 2709-2716.
11. Frleta, D., et al. 2009. Influenza virus and poly(I:C) inhibit MHC class I-restricted presentation of cell-associated antigens derived from infected dead cells captured by human dendritic cells. J. Immunol. 182:2766-2776.
12. Gallimore, A., T. Dumrese, H. Hengartner, R. M. Zinkernagel, and H.-G. Rammensee. 1998. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J. Exp. Med. 187:1647-1657.
13. Ishii, K. J., and S. Akira. 2007. Toll or toll-free adjuvant path toward the optimal vaccine development. J. Clin. Immunol. 27:363-371.
14. Jelinek, I., et al. 2011. TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection. J. Immunol. 186:2422-2429.
15. Kotturi, M. F., et al. 2008. Naive precursor frequencies and MHC binding rather than the degree of epitope diversity shape CD8+ T cell immunodominance. J. Immunol. 181:2124-2133.
16. Le Bon, A., et al. 2003. Cross-priming of CD8+ T cells stimulated by virusinduced type I interferon. Nat. Immunol. 4:1009-1015.
17. Liu, F., J. L. Whitton, and M. K. Slifka. 2004. The rapidity with which virus-specific CD8+ T cells initiate IFN-gamma synthesis increases markedly over the course of infection and correlates with immunodominance. J. Immunol. 173:456-462.
18. Melchionda, F., et al. 2005. Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. J. Clin. Investig. 115:1177-1187.
19. Muzio, M., et al. 2000. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J. Immunol. 164:5998-6004.
20. Oh, J. Z., and R. M. Kedl. 2010. The capacity to induce cross-presentation dictates the success of a TLR7 agonist-conjugate vaccine for eliciting cellular immunity. J. Immunol. 185:4602-4608.
21. Otahal, P., et al. 2005. Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope. J. Immunol. 175:700-712.
22. Pavelic, V., M. S. Matter, S. Mumprecht, I. Breyer, and A. F. Ochsenbein. 2009. CTL induction by cross-priming is restricted to immunodominant epitopes. Eur. J. Immunol. 39:704-716.
23. Prajeeth, C. K., et al. 2010. The synthetic TLR2 agonist BPPcysMPEG leads to efficient cross-priming against co-administered and linked antigens. Eur. J. Immunol. 40:1272-1283.
24. Probst, H. C., et al. 2003. Immunodominance of an antiviral cytotoxic T cell response is shaped by the kinetics of viral protein expression. J. Immunol. 171:5415-5422.
25. Re, F., and J. L. Strominger. 2004. IL-10 released by concomitant TLR2 stimulation blocks the induction of a subset of Th1 cytokines that are specifically induced by TLR4 or TLR3 in human dendritic cells. J. Immunol. 173:7548-7555.
26. Re, F., and J. L. Strominger. 2001. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J. Biol. Chem. 276:37692-37699.
27. Savina, A., et al. 2006. NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell 126:205-218.
28. Schulz, O., et al. 2005. Toll-like receptor 3 promotes cross-priming to virusinfected cells. Nature 433:887-892.
29. Siddiqui, S., A. Alatery, A. Kus, and S. Basta. 2011. TLR engagement prior to virus infection influences MHC-I antigen presentation in an epitopedependent manner as a result of nitric oxide release. J. Leukoc. Biol. 89: 457-468.
30. Siddiqui, S., E. Tarrab, A. Lamarre, and S. Basta. 2010. Altered immunodominance hierarchies of CD8+ T cells in the spleen after infection at different sites is contingent on high virus inoculum. Microbes Infect. 12:324-330.
31. Simmons, D. P., et al. 2010. Mycobacterium tuberculosis and TLR2 agonists inhibit induction of type I IFN and class I MHC antigen cross processing by TLR9. J. Immunol. 185:2405-2415.
32. Trautmann, L., et al. 2005. Selection of T cell clones expressing high-affinity public TCRs within human cytomegalovirus-specific CD8 T cell responses. J. Immunol. 175:6123-6132.
33. Trinchieri, G., and A. Sher. 2007. Cooperation of Toll-like receptor signals in innate immune defence. Nat. Rev. Immunol. 7:179-190.
34. Vanhoutte, F., et al. 2008. Toll-like receptor (TLR)2 and TLR3 synergy and cross-inhibition in murine myeloid dendritic cells. Immunol. Lett. 116:86-94.
35. Vulcano, M., et al. 2004. Toll receptor-mediated regulation of NADPH oxidase in human dendritic cells. J. Immunol. 173:5749-5756.
36. Vyas, J. M., A. G. Van der Veen, and H. L. Ploegh. 2008. The known unknowns of antigen processing and presentation. Nat. Rev. Immunol. 8:607-618.
37. Warger, T., et al. 2006. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 108:544-550.
38. Weck, M. M., et al. 2007. TLR ligands differentially affect uptake and presentation of cellular antigens. Blood 109:3890-3894.
39. Wherry, E. J., J. N. Blattman, K. Murali-Krishna, R. van der Most, and R. Ahmed. 2003. Viral persistence alters CD8 T cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77:4911-4927.
40. Wiesel, M., S. Walton, K. Richter, and A. Oxenius. 2009. Virus-specific CD8 T cells: activation, differentiation and memory formation. Apmis 117:356-381.
41. Wilson, N. S., et al. 2006. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat. Immunol. 7:165-172.
42. Yarovinsky, F., H. Kanzler, S. Hieny, R. L. Coffman, and A. Sher. 2006. Toll-like receptor recognition regulates immunodominance in an antimicrobial CD4+ T cell response. Immunity 25:655-664.
43. Yewdell, J. T., and J. R. Bennink. 1999. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17:51-88.
44. Yewdell, J. W. 2006. Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. Immunity 25:533-543.
45. Zhu, Q., et al. 2010. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J. Clin. Investig. 120:607-616.
46. Zhu, Q., et al. 2008. Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines. Proc. Natl. Acad. Sci. U. S. A. 105:16260-16265.